BI8622 is a specific inhibitor of the ubiquitin ligase HUWE1 with an IC50 of 3.1 µM. BI8622 can decrease the protein expression levels of c-myc and glycolytic markers as well as immune modulatory markers after HUWE1 inhibition in triple-negative breast cancer (TNBC) cell lines. BI8622 significantly protects against cisplatin (HY-17394)-induced acute kidney injury (AKI). BI8622 significantly reduces the growth of multiple myeloma (MM) cell lines and induces cell cycle arrest. BI8622 can prevent HUWE1-dependent TTBK2 ubiquitination. BI8622 can be studied in research for various diseases including medulloblastoma, acute kidney injury, breast cancer and MM[1][2][3][4][5].
Molecular Weight:
426.51
Purity:
99.35
CAS Number:
[1875036-74-0]
Formula:
C25H26N6O
Target:
c-Myc,E1/E2/E3 Enzyme
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted